ISOC1 Inhibitors
Chemical inhibitors of ISOC1 function by impeding various signaling pathways that contribute to the protein's activity within the cell. LY294002 and Wortmannin, for instance, target phosphoinositide 3-kinases (PI3K), which are pivotal in the activation of downstream molecules that can regulate ISOC1 activity. By inhibiting PI3K, these compounds prevent the phosphorylation events necessary for the subsequent activation of proteins involved in the pathways ISOC1 operates in, leading to a decrease in its functional activity. Similarly, PD98059 and U0126 exert their effects by selectively inhibiting mitogen-activated protein kinase kinase (MEK), a kinase that is upstream of the extracellular signal-regulated kinases (ERK). ERK pathways are known to regulate a variety of proteins, and by obstructing the MEK-ERK signaling cascade, PD98059 and U0126 effectively limit the functional activity of ISOC1.
Furthermore, SP600125 inhibits c-Jun N-terminal kinase (JNK), which is involved in regulating responses to stress and inflammation, processes in which ISOC1 may play a role. By blocking JNK, SP600125 can impede the functional activity of ISOC1. SB203580, another chemical inhibitor, targets p38 MAP kinase, which is implicated in the control of a host of proteins, including ISOC1. Inhibition of p38 MAPK by SB203580 can therefore disrupt ISOC1's functional activity. PP2 and Y-27632 are inhibitors of Src family kinases and Rho-associated protein kinase (ROCK), respectively, both of which are involved in signaling pathways that can regulate ISOC1 activity. PP2 and Y-27632 can decrease ISOC1 functional activity by inhibiting these kinases. PD173074 and SU5402 are both FGFR inhibitors that, by blocking FGFR signaling, disrupt downstream signaling pathways critical for ISOC1's function, leading to its inhibition. Lastly, Dorsomorphin and LDN-193189 inhibit AMP-activated protein kinase (AMPK) and BMP signaling, respectively. Since ISOC1's activity may be regulated by these pathways, inhibition by Dorsomorphin and LDN-193189 can lead to a decrease in ISOC1 function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways, including those that may regulate the activity of ISOC1. By inhibiting PI3K, this compound can reduce the phosphorylation and activation of downstream targets that could be crucial for ISOC1's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. By inhibiting PI3K, it prevents the activation of downstream signaling pathways necessary for the functional activity of ISOC1, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). ERK pathways can regulate proteins like ISOC1, and inhibition of MEK thus prevents ERK pathway-mediated functional activation of ISOC1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also functions as a MEK inhibitor, blocking the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which may be necessary for ISOC1's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is involved in stress and inflammatory responses. ISOC1, through its involvement in cellular processes, may be regulated by JNK signaling. Inhibition of JNK can therefore impede ISOC1 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAPK pathway is implicated in the regulation of a wide range of proteins, including ISOC1. By inhibiting p38 MAPK, this compound can disrupt the functional activity of ISOC1. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Src kinases are involved in various signaling pathways that can regulate the activity of proteins like ISOC1. Inhibition of Src can lead to a decrease in ISOC1 functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 selectively inhibits the Rho-associated protein kinase (ROCK). ROCK is involved in actin cytoskeleton organization, which may be necessary for ISOC1's function. Inhibition of ROCK can thus disrupt ISOC1's functional activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR inhibitor. By blocking FGFR signaling, it can inhibit downstream pathways that may be critical for ISOC1's function. This would result in functional inhibition of ISOC1. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is a potent and selective FGFR inhibitor. By inhibiting FGFR, SU5402 disrupts downstream signaling necessary for the functional aspects of proteins such as ISOC1. | ||||||